Genetic Technologies Ltd (GENE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Genetic Technologies Ltd (GENE) has a cash flow conversion efficiency ratio of -3.096x as of June 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.67 Million) by net assets ($1.83 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Genetic Technologies Ltd for the company's overall valuation and market capitalisation.
Genetic Technologies Ltd - Cash Flow Conversion Efficiency Trend (2000–2024)
This chart illustrates how Genetic Technologies Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Genetic Technologies Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Genetic Technologies Ltd ranked by their cash flow conversion efficiency. Explore earnings quality score of Genetic Technologies Ltd to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
PLENUM AG NA O.N.
F:PLEK
|
N/A |
|
Yu Group PLC
LSE:YU
|
-0.037x |
|
Sanichi Technology Bhd
KLSE:0133
|
0.025x |
|
Mega Sun City Holdings Bhd
KLSE:0081
|
-0.010x |
|
S4 Capital PLC
LSE:SFOR
|
0.039x |
|
ATI Physical Therapy Inc
NYSE:ATIP
|
-0.071x |
|
Trucknet Enterprise Ltd
TA:TRAN
|
N/A |
|
Click Holdings Limited
NASDAQ:CLIK
|
-0.002x |
Annual Cash Flow Conversion Efficiency for Genetic Technologies Ltd (2000–2024)
The table below shows the annual cash flow conversion efficiency of Genetic Technologies Ltd from 2000 to 2024. View GENE stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-06-30 | $1.83 Million | $-9.68 Million | -5.288x | -507.08% |
| 2023-06-30 | $11.16 Million | $-9.72 Million | -0.871x | -152.89% |
| 2022-06-30 | $16.43 Million | $-5.66 Million | -0.344x | -17.80% |
| 2021-06-30 | $21.53 Million | $-6.30 Million | -0.292x | +28.38% |
| 2020-06-30 | $13.99 Million | $-5.71 Million | -0.408x | +88.09% |
| 2019-06-30 | $1.77 Million | $-6.07 Million | -3.429x | -186.63% |
| 2018-06-30 | $4.71 Million | $-5.64 Million | -1.196x | -85.73% |
| 2017-06-30 | $10.58 Million | $-6.81 Million | -0.644x | +0.95% |
| 2016-06-30 | $11.88 Million | $-7.73 Million | -0.650x | -27.20% |
| 2015-06-30 | $18.96 Million | $-9.69 Million | -0.511x | +91.50% |
| 2014-06-30 | $1.83 Million | $-10.99 Million | -6.012x | -360.56% |
| 2013-06-30 | $5.76 Million | $-7.52 Million | -1.305x | -144.99% |
| 2012-06-30 | $14.40 Million | $-7.67 Million | -0.533x | -262.57% |
| 2011-06-30 | $6.81 Million | $2.23 Million | 0.328x | +143.55% |
| 2010-06-30 | $5.72 Million | $-4.30 Million | -0.753x | -115.70% |
| 2009-06-30 | $17.49 Million | $-6.10 Million | -0.349x | -1815.27% |
| 2008-06-30 | $20.83 Million | $423.68K | 0.020x | -84.38% |
| 2007-06-30 | $16.90 Million | $2.20 Million | 0.130x | +138.82% |
| 2006-06-30 | $18.27 Million | $-6.13 Million | -0.335x | -15.98% |
| 2005-06-30 | $22.75 Million | $-6.58 Million | -0.289x | -9.13% |
| 2004-06-30 | $17.07 Million | $-4.52 Million | -0.265x | -627.25% |
| 2003-06-30 | $27.28 Million | $-993.71K | -0.036x | +65.80% |
| 2002-06-30 | $31.14 Million | $-3.32 Million | -0.107x | -81.95% |
| 2001-06-30 | $38.07 Million | $-2.23 Million | -0.059x | -39.21% |
| 2000-06-30 | $7.58 Million | $-318.68K | -0.042x | -- |
About Genetic Technologies Ltd
Genetic Technologies Limited, a molecular diagnostics company, engages in the provision of predictive genetic testing and risk assessment tools to help physicians manage people's health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company operates through EasyDNA, AffinityDNA, and GeneType/Corporate segments. It offers BREVAGenplus, a clinicall… Read more